Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5984108 | 0.88 | GAA (0.36) | — | |
| SCHEMBL5984252 | 0.86 | MGLL (0.44) | — | |
| SCHEMBL5985457 | 0.85 | — | — | |
| SCHEMBL5984722 | 0.79 | VCAM1 (0.41) | VCAM1 | |
| SCHEMBL5984287 | 0.79 | VCAM1 (0.39) | VCAM1 | |
| SCHEMBL6731511 | 0.78 | ALDH1A1 (0.41) | MAPTKDM4ENLRP3 | |
| SCHEMBL5984127 | 0.78 | VCAM1 (0.45) | VCAM1KDM4E | |
| SCHEMBL5985540 | 0.75 | VCAM1 (0.35) | VCAM1 | |
| SCHEMBL5984262 | 0.74 | VCAM1 (0.33) | VCAM1 | |
| SCHEMBL6731668 | 0.72 | RXRA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998419-B2 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. (US) | 2006-02-14 | — | — | US | disclosed |
| US-6835754-B2 | Administering alpha-(4-hydroxy-3,5-di-tert-butylphenyl)-N-tert-octylnitrone for example | RENOVIS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040198835-A1 | 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2004-10-07 | — | — | US | disclosed |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2002-11-07 | — | — | US | disclosed |
| EP-1135367-A1 | 3,4,5-TRISUBSTITUTED ARYL NITRONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Centaur Pharmaceuticals, Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032567-A1 | 3,4,5-TRISUBSTITUTED ARYL NITRONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRK1, OPRD1 | VCAM1 3354/4885CTSK 2823/4885MAPT 2021/4885 |
| US-20040198835-A1 | 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | NOS1, NOS3, CBR1 | VCAM1 258/4885CTSK 1896/4885MAPT 3819/4885 |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRD1, OPRK1 | VCAM1 3588/4885CTSK 2803/4885MAPT 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.